CA-MATRIXX-SOFTWARE
3.5.2021 12:04:58 CEST | Business Wire | Press release
MATRIXX Software , a global leader in cloud native, 5G monetization solutions, today announced performance results from its IBM Cloud for Telecommunications implementation. Anticipating the urgent need of Communications Service Providers (CSPs) to monetize their 5G investments, MATRIXX Software’s 5G CCS established a performance milestone of 200K transactions per second (TPS) across 100M subscribers running on IBM Cloud for Telecommunications.
With average end-to-end latency of 7.4 milliseconds across all operations, including network gateways and routing, this performance benchmark demonstrates that MATRIXX on IBM Cloud can enable CSPs to run critical network workloads in the cloud at the same or better performance levels as on-premise. MATRIXX successfully delivered seamless scalability for an efficient, flexible cloud native charging solution, which opens the door for CSPs to experiment with new ways of monetizing 5G workloads.
This is an important milestone as 5G represents a $667B opportunity by 2026 and impacts every industry. To explore and test new revenue streams, CSPs need to accelerate their network transformation to handle increased traffic from new services and devices. With more than 30 billion IoT devices predicted by 2025, telco networks and IT infrastructure will need proven capability to scale both vertically and horizontally if they are to manage the 10-20x growth in traffic anticipated from 5G.
Using a simulated blend of 4G and 5G traffic, MATRIXX used the IBM Cloud for Telecommunications, built on Red Hat OpenShift, to provide more flexibility in harnessing data across cloud and on-premises environments. The performance benchmark demonstrates how together, MATRIXX and IBM Cloud for Telecommunications can deliver consistent throughput and latency, which helps enable providers to run critical network workloads such as charging in the cloud.
“As telcos deploy 5G network infrastructure, they are looking for validation of new revenue models that 5G enables,” said Marc Price, MATRIXX CTO. “We have collaborated with IBM to achieve industry-leading metrics on its IBM Cloud for Telecommunications, showcasing for CSPs how their 5G monetization strategies will be achievable as the number and diversity of connected devices increases exponentially.”
This is the first lab outcome since MATRIXX joined IBM’s partner ecosystem. These results demonstrate the seamless scalability of MATRIXX’s patented converged charging technology when combined with the IBM Cloud for Telecommunications. Working in close collaboration, IBM’s Hybrid Cloud Build Team and MATRIXX have developed a blueprint for best practices and configuration requirements they can deliver to CSP’s to address their unique performance targets.
“As 5G transforms the telco industry, many operators face the challenge of managing growing volumes of data, voice, and multi-media services from millions of end users. The IBM Cloud for Telecommunications is designed to address these specific challenges and transform their networks into flexible platforms that can efficiently scale,” said Steve Goetz, Vice President & Senior Partner of Global Telecommunications, Media & Entertainment Industry at IBM. “As a leading Network and 5G Transformation partner, IBM Global Business Services is proud to support our ecosystem partner MATRIXX to help them achieve such a notable milestone. These results will accelerate business transformation and agility as customers modernize enterprise applications and infrastructure to unlock the power of 5G and edge.”
With innovations in business rule execution, transaction processing, data management and clustering, the cloud native MATRIXX 5G CCS delivers consistent throughput and latency within heterogenous network environments, managing sophisticated price plans, across hundreds of millions of unique subscribers and devices.
MATRIXX is part of IBM's partner ecosystem collaborating on the IBM Cloud for Telecommunications to help network equipment providers, independent software vendors (ISVs), software-as-a-service providers, and hardware partners accelerate business transformation by unlocking the power of 5G and edge. The IBM Cloud for Telecommunications is an open, hybrid cloud architecture that leverages Red Hat OpenShift and IBM Cloud Satellite to enable clients to deploy IBM Cloud services anywhere: on the cloud, on premises or at the edge, while addressing unique industry regulatory and security requirements. The IBM Hybrid Cloud Build Team is an elite team dedicated to help partners maximize the value of open hybrid cloud environments and unlock the power of AI for their business and customers.
To learn more about the collaboration between MATRIXX and IBM, watch this video interview between Marc Price and Omkar Nimbalkar, VP WW Hybrid Cloud Build Team at IBM Hybrid Cloud Ecosystem Group.
About MATRIXX Software
MATRIXX Software is the global leader in 5G monetization for the communications industry. Serving many of the world’s largest operator groups, regional carriers, and emerging digital service providers, MATRIXX delivers a cloud native digital commerce solution that enables unmatched commercial and operational agility. Unifying IT & networks, MATRIXX delivers a network-grade converged charging system (CCS), enabling efficient hyper-scaling of infrastructure to support consumer services, wholesale and enterprise marketplaces. Through its relentless commitment to product excellence and customer success, MATRIXX empowers businesses to harness network assets and business agility to succeed at web scale.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005238/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom